FP
NVCR icon

Financial Perspectives’s NovoCure NVCR Stock Holding History

Financial Perspectives’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9
Closed -$684 – 699
2022
Q3 		$684 Hold
9
– – ﹤0.01% 643
2022
Q2 		$626 Hold
9
– – ﹤0.01% 645
2022
Q1 		$746 Hold
9
– – ﹤0.01% 644
2021
Q4 		$676 Buy
+9
New +$903 ﹤0.01% 617

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Financial Perspectives's NVCR Position: Q4 2022 in Review

Financial Perspectives sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 9 shares — an estimated $684 sold.

Financial Perspectives first reported a position in NVCR in Q4 2021 and held it in 4 quarters. The position peaked at $746 in Q1 2022. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

  • Financial Perspectives reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
  • Financial Perspectives sold 9 NovoCure shares in Q4 2022, an estimated $684.
  • Financial Perspectives first reported a position in NovoCure in Q4 2021 and held it in 4 quarters.
  • Financial Perspectives's NovoCure position peaked at $746 in Q1 2022.
  • 304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Financial Perspectives's 13F filing for Q4 2022, filed 10 Jan 2024.